NCT02923349 · FLOW

Participant flow

A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors · Source last updated 2025-08-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

description
INCAGN01949 7mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors
id
FG000
title
PART 1 Dose 1 (7 mg)
description
INCAGN01949 20mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors
id
FG001
title
PART 1 Dose 2 (20 mg)
description
INCAGN01949 70mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors
id
FG002
title
PART 1 Dose 3 (70 mg)
description
INCAGN01949 200mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors
id
FG003
title
PART 1 Dose 4 (200 mg)
description
INCAGN01949 350mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors
id
FG004
title
PART 1 Dose 5 (350 mg)
description
INCAGN01949 700mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors
id
FG005
title
PART 1 Dose 6 (700 mg)
description
INCAGN01949 1400mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors
id
FG006
title
PART 1 Dose 7 (1400 mg)

periods

drop Withdraws
reasons
group Id
FG000
num Subjects
1
group Id
FG001
num Subjects
2
group Id
FG002
num Subjects
4
group Id
FG003
num Subjects
1
group Id
FG004
num Subjects
3
group Id
FG005
num Subjects
0
group Id
FG006
num Subjects
1
type
Other
reasons
group Id
FG000
num Subjects
2
group Id
FG001
num Subjects
2
group Id
FG002
num Subjects
8
group Id
FG003
num Subjects
10
group Id
FG004
num Subjects
12
group Id
FG005
num Subjects
3
group Id
FG006
num Subjects
0
type
Withdrawal by Subject
reasons
group Id
FG000
num Subjects
0
group Id
FG001
num Subjects
0
group Id
FG002
num Subjects
0
group Id
FG003
num Subjects
1
group Id
FG004
num Subjects
1
group Id
FG005
num Subjects
0
group Id
FG006
num Subjects
2
type
Physician Decision
reasons
group Id
FG000
num Subjects
0
group Id
FG001
num Subjects
0
group Id
FG002
num Subjects
3
group Id
FG003
num Subjects
0
group Id
FG004
num Subjects
1
group Id
FG005
num Subjects
1
group Id
FG006
num Subjects
0
type
Lost to Follow-up
reasons
group Id
FG000
num Subjects
1
group Id
FG001
num Subjects
0
group Id
FG002
num Subjects
2
group Id
FG003
num Subjects
4
group Id
FG004
num Subjects
2
group Id
FG005
num Subjects
3
group Id
FG006
num Subjects
0
type
Death
milestones
achievements
group Id
FG000
num Subjects
4
group Id
FG001
num Subjects
4
group Id
FG002
num Subjects
22
group Id
FG003
num Subjects
18
group Id
FG004
num Subjects
23
group Id
FG005
num Subjects
12
group Id
FG006
num Subjects
4
type
STARTED
achievements
group Id
FG000
num Subjects
0
group Id
FG001
num Subjects
0
group Id
FG002
num Subjects
5
group Id
FG003
num Subjects
2
group Id
FG004
num Subjects
4
group Id
FG005
num Subjects
5
group Id
FG006
num Subjects
1
type
COMPLETED
achievements
group Id
FG000
num Subjects
4
group Id
FG001
num Subjects
4
group Id
FG002
num Subjects
17
group Id
FG003
num Subjects
16
group Id
FG004
num Subjects
19
group Id
FG005
num Subjects
7
group Id
FG006
num Subjects
3
type
NOT COMPLETED
title
Overall Study

pre Assignment Details

A total of 129 participants were screened for this study, of which 42 participants were screen failures and 87 participants were randomized to treatment.

recruitment Details

The study was conducted at 4 different sites in US, 1 site in Switzerland,1 site in Spain and 2 sites in the United Kingdom.

Complete source fields